

Investment Company Report

CLARITY PHARMACEUTICALS LTD

Security	Q2517S102	Meeting Type	Annual General Meeting
Ticker Symbol		Meeting Date	23-Nov-2023
ISIN	AU0000165375	Agenda	717824709 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
CMMT	VOTING EXCLUSIONS APPLY TO THIS MEETING FOR PROPOSALS 1,4,5,6 AND VOTES CAST-BY ANY INDIVIDUAL OR RELATED PARTY WHO BENEFIT FROM THE PASSING OF THE-PROPOSAL/S WILL BE DISREGARDED BY THE COMPANY. HENCE, IF YOU HAVE OBTAINED-BENEFIT OR EXPECT TO OBTAIN FUTURE BENEFIT (AS REFERRED IN THE COMPANY-ANNOUNCEMENT) VOTE ABSTAIN ON THE RELEVANT PROPOSAL ITEMS. BY DOING SO, YOU-ACKNOWLEDGE THAT YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN BENEFIT BY THE-PASSING OF THE RELEVANT PROPOSAL/S. BY VOTING (FOR OR AGAINST) ON THE ABOVE-MENTIONED PROPOSAL/S, YOU ACKNOWLEDGE THAT YOU HAVE NOT OBTAINED BENEFIT-NEITHER EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S-AND YOU COMPLY WITH THE VOTING EXCLUSION	Non-Voting		
1	REMUNERATION REPORT	Management	For	For
2	RE-ELECTION OF DIRECTOR - MS CHERYL MALEY	Management	For	For
3	RE-ELECTION OF DIRECTOR - DR ALAN TAYLOR	Management	For	For
4	ISSUE OF OPTIONS - DR ALAN TAYLOR (EXECUTIVE CHAIR)	Management	For	For
5	ISSUE OF OPTIONS - DR COLIN BIGGIN (MANAGING DIRECTOR / CHIEF EXECUTIVE OFFICER)	Management	For	For
6	INCREASE OF NON-EXECUTIVE DIRECTOR FEE POOL	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
131268	PORT LIFE SCI ALT FD	131268	BANK OF NEW YORK MELLON	300,235	0	16-Nov-2023	16-Nov-2023

Investment Company Report

TELIX PHARMACEUTICALS LTD

Security	Q8973A105	Meeting Type	Ordinary General Meeting
Ticker Symbol		Meeting Date	05-Apr-2024
ISIN	AU000000TLX2	Agenda	718216989 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
CMMT	VOTING EXCLUSIONS APPLY TO THIS MEETING FOR PROPOSALS 1 TO 7 AND VOTES CAST-BY ANY INDIVIDUAL OR RELATED PARTY WHO BENEFIT FROM THE PASSING OF THE-PROPOSAL/S WILL BE DISREGARDED BY THE COMPANY. HENCE, IF YOU HAVE OBTAINED-BENEFIT OR EXPECT TO OBTAIN FUTURE BENEFIT (AS REFERRED IN THE COMPANY-ANNOUNCEMENT) VOTE ABSTAIN ON THE RELEVANT PROPOSAL ITEMS. BY DOING SO, YOU-ACKNOWLEDGE THAT YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN BENEFIT BY THE-PASSING OF THE RELEVANT PROPOSAL/S. BY VOTING (FOR OR AGAINST) ON THE ABOVE-MENTIONED PROPOSAL/S, YOU ACKNOWLEDGE THAT YOU HAVE NOT OBTAINED BENEFIT-NEITHER EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S-AND YOU COMPLY WITH THE VOTING EXCLUSION	Non-Voting		
1	RATIFY THE ISSUE OF THE DEDICAID CONSIDERATION SHARES	Management	For	For
2	RATIFY THE ISSUE OF THE LIGHTPOINT CONSIDERATION SHARES	Management	For	For
3	RATIFY THE ISSUE OF THE LIGHTPOINT RIGHTS	Management	For	For
4	APPROVAL TO ISSUE THE QSAM CONSIDERATION SHARES	Management	For	For
5	APPROVAL TO ISSUE THE QSAM RIGHTS	Management	For	For
6	APPROVAL TO ISSUE THE ISOTHERAPEUTICS CONSIDERATION SHARES	Management	For	For
7	APPROVAL TO ISSUE THE ARTMS CONSIDERATION SHARES	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
131268	PORT LIFE SCI ALT FD	131268	BANK OF NEW YORK MELLON	110,676	0	26-Mar-2024	26-Mar-2024

Investment Company Report

LANTHEUS HOLDINGS, INC.

Security	516544103	Meeting Type	Annual
Ticker Symbol	LNTH	Meeting Date	25-Apr-2024
ISIN	US5165441032	Agenda	935993041 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class III Director: Mr. Brian Markison	Management	For	For
1.2	Election of Class III Director: Mr. Gary Pruden	Management	For	For
1.3	Election of Class III Director: Dr. James H. Thrall	Management	For	For
2.	The approval, on an advisory basis, of the compensation paid to our named executive officers.	Management	For	For
3.	The approval of an amendment to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan to increase the number of Shares reserved for issuance thereunder.	Management	For	For
4.	The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	4,400	0	22-Mar-2024	22-Mar-2024

Investment Company Report

DANAHER CORPORATION

Security	235851102	Meeting Type	Annual
Ticker Symbol	DHR	Meeting Date	07-May-2024
ISIN	US2358511028	Agenda	935997506 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to hold office until the 2025 Annual Meeting: Rainer M. Blair	Management	For	For
1b.	Election of Director to hold office until the 2025 Annual Meeting: Feroz Dewan	Management	For	For
1c.	Election of Director to hold office until the 2025 Annual Meeting: Linda Filler	Management	For	For
1d.	Election of Director to hold office until the 2025 Annual Meeting: Teri List	Management	For	For
1e.	Election of Director to hold office until the 2025 Annual Meeting: Jessica L. Mega, MD, MPH	Management	For	For
1f.	Election of Director to hold office until the 2025 Annual Meeting: Mitchell P. Rales	Management	For	For
1g.	Election of Director to hold office until the 2025 Annual Meeting: Steven M. Rales	Management	For	For
1h.	Election of Director to hold office until the 2025 Annual Meeting: Pardis C. Sabeti, MD, D. PHIL	Management	For	For
1i.	Election of Director to hold office until the 2025 Annual Meeting: A. Shane Sanders	Management	For	For
1j.	Election of Director to hold office until the 2025 Annual Meeting: John T. Schwieters	Management	For	For
1k.	Election of Director to hold office until the 2025 Annual Meeting: Alan G. Spoon	Management	For	For
1l.	Election of Director to hold office until the 2025 Annual Meeting: Raymond C. Stevens, Ph.D	Management	For	For
1m.	Election of Director to hold office until the 2025 Annual Meeting: Elias A. Zerhouni, MD	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2024.	Management	For	For
3.	To approve on an advisory basis the Company's named executive officer compensation.	Management	For	For
4.	To act upon a shareholder proposal requesting that Danaher amend its governing documents to reduce the percentage of shares required for shareholders to call a special meeting of shareholders from 25% to 15%.	Shareholder	Against	For
5.	To act upon a shareholder proposal requesting a report to shareholders on the effectiveness of the Company's diversity, equity and inclusion efforts.	Shareholder	Against	For

Investment Company Report

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	700	0	22-Apr-2024	22-Apr-2024

Investment Company Report

TELIX PHARMACEUTICALS LTD

Security	Q8973A105	Meeting Type	Annual General Meeting
Ticker Symbol		Meeting Date	22-May-2024
ISIN	AU000000TLX2	Agenda	718484493 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
CMMT	VOTING EXCLUSIONS APPLY TO THIS MEETING FOR PROPOSALS 1, 3, 4 AND 5 VOTES-CAST BY ANY INDIVIDUAL OR RELATED PARTY WHO BENEFIT FROM THE PASSING OF THE-PROPOSAL/S WILL BE DISREGARDED BY THE COMPANY. HENCE, IF YOU HAVE OBTAINED-BENEFIT OR EXPECT TO OBTAIN FUTURE BENEFIT (AS REFERRED IN THE COMPANY-ANNOUNCEMENT) VOTE ABSTAIN ON THE RELEVANT PROPOSAL ITEMS. BY DOING SO, YOU-ACKNOWLEDGE THAT YOU HAVE OBTAINED BENEFIT OR EXPECT TO OBTAIN BENEFIT BY THE-PASSING OF THE RELEVANT PROPOSAL/S. BY VOTING (FOR OR AGAINST) ON THE ABOVE-MENTIONED PROPOSAL/S, YOU ACKNOWLEDGE THAT YOU HAVE NOT OBTAINED BENEFIT-NEITHER EXPECT TO OBTAIN BENEFIT BY THE PASSING OF THE RELEVANT PROPOSAL/S-AND YOU COMPLY WITH THE VOTING EXCLUSION	Non-Voting		
CMMT	PLEASE NOTE THAT THIS IS AN AMENDMENT TO MEETING ID 162920 DUE TO RECEIVED-CHANGE IN BOARD RECOMMENDATION FOR RESOLUTIONS 1, 3 AND 5. ALL VOTES RECEIVED-ON THE PREVIOUS MEETING WILL BE DISREGARDED AND YOU WILL NEED TO REINSTRUCT-ON THIS MEETING NOTICE. THANK YOU.	Non-Voting		
1	ADOPT THE 2023 REMUNERATION REPORT	Management	For	
2	RE-ELECT DR ANDREAS KLUGE AS DIRECTOR	Management	For	For
3	APPROVE THE AMENDED EQUITY INCENTIVE PLAN AND THE GRANT OF EQUITY SECURITIES UNDER THE EQUITY INCENTIVE PLAN	Management	For	
4	APPROVE THE GRANT OF PERFORMANCE SHARE APPRECIATION RIGHTS TO THE MANAGING DIRECTOR AND GROUP CHIEF EXECUTIVE OFFICER	Management	For	For
5	APPROVE AN INCREASE IN THE MAXIMUM AGGREGATE REMUNERATION OF THE NON-EXECUTIVE DIRECTORS	Management	For	

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
131268	PORT LIFE SCI ALT FD	131268	BANK OF NEW YORK MELLON	119,676	0	29-Apr-2024	29-Apr-2024

Investment Company Report

ARVINAS, INC.

Security	04335A105	Meeting Type	Annual
Ticker Symbol	ARVN	Meeting Date	29-May-2024
ISIN	US04335A1051	Agenda	936039002 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Edward Kennedy, Jr.		For	For
	2 Everett Cunningham		For	For
	3 Briggs Morrison, M.D.		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	5,000	0	18-Apr-2024	18-Apr-2024

Investment Company Report

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	31-May-2024
ISIN	US0311621009	Agenda	936043140 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. Michael V. Drake	Management	For	For
1d.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. Brian J. Druker	Management	For	For
1e.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Mr. Robert A. Eckert	Management	For	For
1f.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Mr. Greg C. Garland	Management	For	For
1g.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Mr. Charles M. Holley, Jr.	Management	For	For
1h.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. S. Omar Ishrak	Management	For	For
1i.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. Tyler Jacks	Management	For	For
1j.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Dr. Mary E. Klotman	Management	For	For
1k.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Ms. Ellen J. Kullman	Management	For	For
1l.	Election of Director to serve for a term of office expiring at the 2025 annual meeting of stockholders: Ms. Amy E. Miles	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To approve our Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2024.	Management	For	For

Investment Company Report

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	750	0	22-Apr-2024	22-Apr-2024

Investment Company Report

PERSPECTIVE THERAPEUTICS, INC.

Security	46489V104	Meeting Type	Annual
Ticker Symbol	CATX	Meeting Date	31-May-2024
ISIN	US46489V1044	Agenda	936044483 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Lori A. Woods		For	For
	2 Heidi Henson		For	For
	3 R. F. Williamson, III		For	For
	4 F. Morich, MD, PhD		For	For
	5 Johan (Thijs) Spoor		For	For
2.	To consider and vote on a proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1:10 (the "Reverse Stock Split"), with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's board of directors in its sole discretion (the "Reverse Stock Split Proposal").	Management	For	For
3.	To consider and vote on a proposal to ratify the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.	Management	For	For
4.	To consider and vote on a proposal to approve the Company's Third Amended and Restated 2020 Equity Incentive Plan.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	342,550	0	23-May-2024	23-May-2024

Investment Company Report

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	05-Jun-2024
ISIN	US07725L1026	Agenda	936074741 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1	THAT Dr. Olivier Brandicourt be and is hereby re-elected to ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
2	THAT Donald W. Glazer be and is hereby re-elected to serve as a ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
3	THAT Michael Goller be and is hereby re-elected to serve as a ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
4	THAT Dr. Corazon (Corsee) D. Sanders be and is hereby re-elected ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
5	THAT the appointment of Ernst & Young LLP, Ernst & Young and ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
6	THAT the Board of Directors is hereby authorized to fix the ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
7	THAT the granting of a share issue mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
8	THAT the granting of a share repurchase mandate to the Board of ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
9	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
10	THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
11	THAT the grant of restricted share units ("RSUs") with a grant ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
12	THAT the grant of performance share units ("PSUs") with a grant ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
13	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
14	THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against

Investment Company Report

15	THAT, on a non-binding, advisory basis, the compensation of the ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
16	THAT, on a non-binding, advisory basis, the frequency of future ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
17a	THAT the Third Amended and Restated 2016 Share Option and ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
17b	THAT the consultant sublimit set out in the Third Amended and ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
18	THAT the Fourth Amended and Restated 2018 Employee Share ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against
19	THAT the adjournment of the Annual Meeting by the chairman, if ...(due to space limits, see proxy material for full proposal).	Management	Abstain	Against

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	1,500	0	23-May-2024	23-May-2024

Investment Company Report

IGM BIOSCIENCES, INC.

Security	449585108	Meeting Type	Annual
Ticker Symbol	IGMS	Meeting Date	11-Jun-2024
ISIN	US4495851085	Agenda	936050842 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 M. K. Behrens, Ph.D.		For	For
	2 E.H.Z. Thompson, Ph.D.		For	For
	3 Christina Teng Topsøe		For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.	Management	For	For
3.	Approval of an amendment to our amended and restated certificate of incorporation to limit the liability of certain officers as permitted by Delaware law.	Management	Against	Against
4.	Approval of a stock option exchange program for employees (excluding our chief executive officer and non-employee directors).	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	1,200	0	03-May-2024	03-May-2024

Investment Company Report

IOVANCE BIOTHERAPEUTICS, INC.

Security	462260100	Meeting Type	Annual
Ticker Symbol	IOVA	Meeting Date	11-Jun-2024
ISIN	US4622601007	Agenda	936067467 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Iain Dukes, D. Phil.		For	For
	2 Athena Countouriotis MD		For	For
	3 Ryan Maynard		For	For
	4 Wayne P. Rothbaum		For	For
	5 Frederick G Vogt PhD JD		For	For
	6 Michael Weiser, MD, PhD		For	For
	7 Wendy Yarno		For	For
2.	To approve, by non-binding advisory vote, the compensation of our named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.	Management	For	For
4.	To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from the 2014 Equity Incentive Plan.	Management	For	For
5.	To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	20,000	0	23-May-2024	23-May-2024

Investment Company Report

RADNET, INC.

Security	750491102	Meeting Type	Annual
Ticker Symbol	RDNT	Meeting Date	12-Jun-2024
ISIN	US7504911022	Agenda	936054256 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Howard G. Berger, M.D.		For	For
	2 Christine N. Gordon		For	For
	3 A. Gregory Sorensen, MD		For	For
	4 Laura P. Jacobs		For	For
	5 Lawrence L. Levitt		For	For
	6 Gregory E. Spurlock		For	For
	7 David L. Swartz		For	For
2.	The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.	Management	For	For
3.	An advisory vote to approve the compensation of the Company's Named Executive Officers.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	2,500	0	03-May-2024	03-May-2024

Investment Company Report

SCHRODINGER, INC.

Security	80810D103	Meeting Type	Annual
Ticker Symbol	SDGR	Meeting Date	18-Jun-2024
ISIN	US80810D1037	Agenda	936060968 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director to serve until the 2027 Annual Meeting of Stockholders: Ramy Farid	Management	For	For
1b.	Election of Class I Director to serve until the 2027 Annual Meeting of Stockholders: Gary Ginsberg	Management	For	For
1c.	Election of Class I Director to serve until the 2027 Annual Meeting of Stockholders: Arun Oberoi	Management	For	For
2.	Approval of an advisory vote on executive compensation.	Management	For	For
3.	Approval of an amendment to the Schrödinger, Inc. 2022 Equity Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 5,000,000 shares.	Management	For	For
4.	Approval of an amendment to the Schrödinger, Inc. 2020 Employee Stock Purchase Plan to increase the number of shares of common stock available for issuance thereunder by 413,155 shares.	Management	For	For
5.	Approval of an amendment to the Schrödinger, Inc. Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.	Management	Against	Against
6.	Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	3,900	0	23-May-2024	23-May-2024

Investment Company Report

BRIDGEBIO PHARMA INC.

Security	10806X102	Meeting Type	Annual
Ticker Symbol	BBIO	Meeting Date	21-Jun-2024
ISIN	US10806X1028	Agenda	936064889 - Management

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Eric Aguiar, M.D.		For	For
	2 Jennifer E. Cook		For	For
	3 Andrea J. Ellis		For	For
	4 Fred Hassan		For	For
	5 Ali J. Satvat		For	For
2.	To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.	Management	For	For
4.	To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.	Management	For	For

Account Number	Account Name	Internal Account	Custodian	Ballot Shares	Unavailable Shares	Vote Date	Date Confirmed
000131268	PORT LIFE SCI ALT FD	PLSAF - MELLON	BNY MELLON	6,500	0	03-May-2024	03-May-2024